As Drug Resistance Grows, Amplyx Tests New Antifungal Drug
Summary
One such fungus, Candida auris , like some bacteria, has become increasingly resistant to the drugs with which it was previously treated, causing infections across five continents, as the New York Times recently reported in an article about the rise of the “mysterious” worldwide health threat. Now, a San Diego company is testing an experimental drug to treat life-threatening, invasive infections caused by not only strains of Candida, but also Aspergillis and rare molds. Funded by over a hundred million dollars in venture investment, plus grants from the National Institutes of Health, Amplyx is enrolling patients in Phase 2 trials of its lead drug candidate, APX001A. Scynexis (NASDAQ: SCYX ), a New Jersey-based spinout of Aventis (which has since merged with Sanofi), is in late-stage testing of ibrexafungerp , which it says can treat multiple fungal infections, including some that have demonstrated resistance to existing therapies. The CDC has been keeping an especially close eye on Candida auris because of its ability to spread easily in hospitals and long-term care facilities.
Classifications
AskAI Classifications
LabelsLinked Companies
